<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28183">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02739828</url>
  </required_header>
  <id_info>
    <org_study_id>P15-692</org_study_id>
    <nct_id>NCT02739828</nct_id>
  </id_info>
  <brief_title>Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients</brief_title>
  <acronym>HOPE</acronym>
  <official_title>Post Marketing Observational Study to Assess Quality of Life Changes in Swedish Patients With Moderate or Severe Hidradenitis Suppurativa (HS) After 6 Months on Adalimumab Treatment (HOPE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess quality of life (QoL), skin pain, work
      productivity/activity and health related problems in Swedish patients with moderate to
      severe HS before and after 6 months treatment with Adalimumab. The patients will be treated
      in accordance with normal routine clinical care.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>From Week 0 to Week 12</time_frame>
    <description>The Dermatology Life Quality Index (DLQI) is a 10-question validated dermatologic disease questionnaire to measure quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Patient's Global Assessment of Skin Pain - numerical rating scale (NRS)</measure>
    <time_frame>Week 4, 12 and 24</time_frame>
    <description>Pain will be rated from 0 (no skin pain) to 10 (skin pain as bad as you can imagine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EuroQol 5 Dimensions (EQ-5D)</measure>
    <time_frame>Week 4, 12 and 24</time_frame>
    <description>The EQ-5D is a five dimensions generic questionnaire used to measure health-related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hidradenitis Suppurativa Impact Assessment (HSIA)</measure>
    <time_frame>Week 4, 12 and 24</time_frame>
    <description>The Hidradenitis Suppurativa Impact Assessment (HSIA) is a disease specific questionnaire measuring the impact the patient experiences associated with HS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP)</measure>
    <time_frame>Week 4, 12 and 24</time_frame>
    <description>The Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) measures work productivity and activity impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hidradenitis Suppurativa Clinical Response (HiSCR)</measure>
    <time_frame>Week 4, 12 and 24</time_frame>
    <description>HiSCR assesses HS inflammatory signs and symptoms that will determine clinical effectiveness.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hidradenitis Suppurativa</condition>
  <arm_group>
    <arm_group_label>Patients with Hidradenitis Suppurativa</arm_group_label>
    <description>Patients with moderate or severe HS treated prescribed adalimumab according to the Swedish Summary of Product Characteristics and treated as per routine clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Adalimumab</description>
    <arm_group_label>Patients with Hidradenitis Suppurativa</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with moderate or severe Hidradenitis Suppurativa
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Hidradenitis Suppurativa

          -  Prescribed Adalimumab according to the Summary of Product Characteristics (SmPC)

          -  Willingness to sign and date a Patient Information/Informed Consent Form

        Exclusion Criteria:

          -  Prior biologic treatment discontinued &lt;6 months before the baseline visit

          -  Patient not able to understand the language of the provided patient questionnaires

          -  History of non-compliance with medication or a medical history that could enhance
             non-compliance with medication, as determined by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Dahl, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical Affairs, AbbVie Sweden AB</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helena Wicktor, MS</last_name>
    <phone>+46 70 257 05 44</phone>
    <email>helena.wicktor@abbvie.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ewa Berndtson</last_name>
    <phone>+46 70 337 43 73</phone>
    <email>ewa.berndtson@abbvie.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 147564</name>
      <address>
        <city>Halmstad</city>
        <zip>301 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 147564, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 147565</name>
      <address>
        <city>Karlskrona</city>
        <zip>SE-37185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 147565</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 147563</name>
      <address>
        <city>Linkoping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 147563, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148232</name>
      <address>
        <city>Lund</city>
        <zip>SE 221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148232, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 147329</name>
      <address>
        <city>Solna</city>
        <zip>SE 171 29</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 159946</name>
      <address>
        <city>Stockholm</city>
        <zip>112 51</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 159946, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 147562</name>
      <address>
        <city>Stockholm</city>
        <zip>118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 147562, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148233</name>
      <address>
        <city>Stockholm</city>
        <zip>182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148233, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 147561</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 147561, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148234</name>
      <address>
        <city>Trelleborg</city>
        <zip>231 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148234, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148235</name>
      <address>
        <city>Umea</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148235, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148231</name>
      <address>
        <city>Umea</city>
        <zip>SE-901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148231, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com/</url>
  </link>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 20, 2017</lastchanged_date>
  <firstreceived_date>April 12, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hidradenitis</mesh_term>
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
